Skip to content 
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California. more
| Time Frame | CALC | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 16.67% | -1.08% | -1.38% |
| 1-Month Return | -87.39% | -0.47% | -1.81% |
| 3-Month Return | -78.33% | 2.13% | 1.38% |
| 6-Month Return | -70.4% | 17.04% | 5.68% |
| 1-Year Return | -73.78% | 6.56% | 11.74% |
| 3-Year Return | -92.4% | 16.78% | 65.15% |
| 5-Year Return | -99.82% | 34.34% | 73.68% |
| 10-Year Return | -99.7% | 137.88% | 260.03% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | 395.00K | 519.00K | 52.00K | 58.00K | 58.00K | [{"date":"2020-12-31","value":76.11,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":10.02,"profit":true},{"date":"2023-12-31","value":11.18,"profit":true},{"date":"2024-12-31","value":11.18,"profit":true}] |
| Gross Profit | (395.00K) | (519.00K) | (52.00K) | (58.00K) | (58.00K) | [{"date":"2020-12-31","value":-39500000,"profit":false},{"date":"2021-12-31","value":-51900000,"profit":false},{"date":"2022-12-31","value":-5200000,"profit":false},{"date":"2023-12-31","value":-5800000,"profit":false},{"date":"2024-12-31","value":-5800000,"profit":false}] |
| Gross Margin | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 29.83M | 35.95M | 14.19M | 38.08M | 24.20M | [{"date":"2020-12-31","value":78.35,"profit":true},{"date":"2021-12-31","value":94.41,"profit":true},{"date":"2022-12-31","value":37.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":63.57,"profit":true}] |
| Operating Income | (29.83M) | (35.95M) | (14.19M) | (38.08M) | (24.20M) | [{"date":"2020-12-31","value":-2983200000,"profit":false},{"date":"2021-12-31","value":-3594700000,"profit":false},{"date":"2022-12-31","value":-1419300000,"profit":false},{"date":"2023-12-31","value":-3807500000,"profit":false},{"date":"2024-12-31","value":-2420400000,"profit":false}] |
| Total Non-Operating Income/Expense | 2.30M | (1.23M) | 6.94M | 3.61M | - | [{"date":"2020-12-31","value":33.14,"profit":true},{"date":"2021-12-31","value":-17.66,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":51.96,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Pre-Tax Income | (27.53M) | (35.82M) | (7.82M) | (34.36M) | (13.70M) | [{"date":"2020-12-31","value":-2753100000,"profit":false},{"date":"2021-12-31","value":-3582100000,"profit":false},{"date":"2022-12-31","value":-782400000,"profit":false},{"date":"2023-12-31","value":-3435700000,"profit":false},{"date":"2024-12-31","value":-1370000000,"profit":false}] |
| Income Taxes | (538.00K) | (2.00M) | 2.39M | (109.89K) | - | [{"date":"2020-12-31","value":-22.53,"profit":false},{"date":"2021-12-31","value":-83.63,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-4.6,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | (26.99M) | (33.82M) | (10.21M) | (34.25M) | - | [{"date":"2020-12-31","value":-2699300000,"profit":false},{"date":"2021-12-31","value":-3382400000,"profit":false},{"date":"2022-12-31","value":-1021200000,"profit":false},{"date":"2023-12-31","value":-3424710500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (27.53M) | (35.82M) | (35.60M) | (34.36M) | (13.70M) | [{"date":"2020-12-31","value":-2753100000,"profit":false},{"date":"2021-12-31","value":-3582100000,"profit":false},{"date":"2022-12-31","value":-3560500000,"profit":false},{"date":"2023-12-31","value":-3435700000,"profit":false},{"date":"2024-12-31","value":-1370000000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (27.53M) | (35.82M) | (7.82M) | (34.36M) | (13.70M) | [{"date":"2020-12-31","value":-2753100000,"profit":false},{"date":"2021-12-31","value":-3582100000,"profit":false},{"date":"2022-12-31","value":-782400000,"profit":false},{"date":"2023-12-31","value":-3435700000,"profit":false},{"date":"2024-12-31","value":-1370000000,"profit":false}] |
| EPS (Diluted) | (4.68) | (23.66) | (24.92) | (25.59) | (2.07) | [{"date":"2020-12-31","value":-468,"profit":false},{"date":"2021-12-31","value":-2366,"profit":false},{"date":"2022-12-31","value":-2492,"profit":false},{"date":"2023-12-31","value":-2559,"profit":false},{"date":"2024-12-31","value":-207,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| CALC | |
|---|---|
| Cash Ratio | 3.83 |
| Current Ratio | 4.04 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CALC | |
|---|---|
| ROA (LTM) | -100.03% |
| ROE (LTM) | -526.36% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CALC | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 1.02 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.02 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CALC | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 6.98 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
CalciMedica, Inc. Common Stock (CALC) share price today is $0.6551
Yes, Indians can buy shares of CalciMedica, Inc. Common Stock (CALC) on Vested. To buy
Yes, you can purchase fractional shares of CalciMedica, Inc. Common Stock (CALC) via the Vested app. You can start investing in CalciMedica, Inc. Common Stock (CALC) with a minimum investment of $1.
You can invest in shares of CalciMedica, Inc. Common Stock (CALC) via Vested in three simple steps:
The 52-week high price of CalciMedica, Inc. Common Stock (CALC) is $7.2. The 52-week low price of CalciMedica, Inc. Common Stock (CALC) is $0.52.
The price-to-earnings (P/E) ratio of CalciMedica, Inc. Common Stock (CALC) is
The price-to-book (P/B) ratio of CalciMedica, Inc. Common Stock (CALC) is 6.98
The dividend yield of CalciMedica, Inc. Common Stock (CALC) is 0.00%
The market capitalization of CalciMedica, Inc. Common Stock (CALC) is $10.09M
The stock symbol (or ticker) of CalciMedica, Inc. Common Stock is CALC
Consider the share price of CalciMedica, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether CalciMedica, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in CalciMedica, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the CalciMedica, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of CalciMedica, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that CalciMedica, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
